ATE409481T1 - Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit - Google Patents
Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheitInfo
- Publication number
- ATE409481T1 ATE409481T1 AT06764942T AT06764942T ATE409481T1 AT E409481 T1 ATE409481 T1 AT E409481T1 AT 06764942 T AT06764942 T AT 06764942T AT 06764942 T AT06764942 T AT 06764942T AT E409481 T1 ATE409481 T1 AT E409481T1
- Authority
- AT
- Austria
- Prior art keywords
- dihydrotetrabenazine
- huntington
- cis
- disease
- treat symptoms
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010008748 Chorea Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000015592 Involuntary movements Diseases 0.000 abstract 1
- 206010028347 Muscle twitching Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 208000012601 choreatic disease Diseases 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000005021 gait Effects 0.000 abstract 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0514501.6A GB0514501D0 (en) | 2005-07-14 | 2005-07-14 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE409481T1 true ATE409481T1 (de) | 2008-10-15 |
Family
ID=34897233
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06764942T ATE409481T1 (de) | 2005-07-14 | 2006-07-13 | Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit |
| AT08017191T ATE522215T1 (de) | 2005-07-14 | 2006-07-13 | Verwendung von 3,11b-cis-dihydrotetrabenazine zur behandlung von symptomen von huntington-chorea |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08017191T ATE522215T1 (de) | 2005-07-14 | 2006-07-13 | Verwendung von 3,11b-cis-dihydrotetrabenazine zur behandlung von symptomen von huntington-chorea |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20080319000A1 (enExample) |
| EP (2) | EP1885363B1 (enExample) |
| JP (1) | JP2009501202A (enExample) |
| KR (1) | KR20080030666A (enExample) |
| CN (1) | CN101282726A (enExample) |
| AT (2) | ATE409481T1 (enExample) |
| AU (1) | AU2006268098B2 (enExample) |
| CA (1) | CA2615077A1 (enExample) |
| CY (1) | CY1108653T1 (enExample) |
| DE (1) | DE602006002982D1 (enExample) |
| DK (1) | DK1885363T3 (enExample) |
| ES (1) | ES2314931T3 (enExample) |
| GB (1) | GB0514501D0 (enExample) |
| HR (1) | HRP20080677T3 (enExample) |
| ME (1) | ME01629B (enExample) |
| NZ (1) | NZ565522A (enExample) |
| PL (1) | PL1885363T3 (enExample) |
| PT (1) | PT1885363E (enExample) |
| RS (1) | RS50626B (enExample) |
| RU (1) | RU2409365C2 (enExample) |
| SI (1) | SI1885363T1 (enExample) |
| WO (1) | WO2007007105A1 (enExample) |
| ZA (1) | ZA200800905B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| GB0516168D0 (en) * | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| GB0810857D0 (en) * | 2008-06-13 | 2008-07-23 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20120208773A1 (en) * | 2008-08-12 | 2012-08-16 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenazine |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| GB2463451A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012095548A2 (es) | 2011-01-13 | 2012-07-19 | Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) | Compuestos para el tratamiento de enfermedades neurodegenerativas |
| CN110691596A (zh) * | 2017-04-01 | 2020-01-14 | 阿德普蒂奥制药有限公司 | 药物组合物 |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US12144899B2 (en) | 2018-04-25 | 2024-11-19 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| GB201808464D0 (en) * | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| KR20220066253A (ko) | 2019-07-16 | 2022-05-24 | 러쉬 유니버시티 메디컬 센터 | 신경퇴행성 장애를 치료하기 위한 벤조에이트 함유 조성물의 용도 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3009918A (en) * | 1961-11-21 | Chz ch | ||
| US2830993A (en) * | 1958-04-15 | Quinolizine derivatives | ||
| US3132147A (en) * | 1964-05-05 | |||
| US3079395A (en) * | 1963-02-26 | Novel z-oxq-benzoquinoliaine | ||
| US3209005A (en) * | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| US3095419A (en) * | 1963-06-25 | Process for preparing z-oxo-j- | ||
| US3123609A (en) * | 1964-03-03 | Benzo | ||
| US3159638A (en) * | 1964-12-01 | Xcha-chj | ||
| US3314966A (en) * | 1967-04-18 | Substituted benzo[a]quinolizines | ||
| US2954382A (en) * | 1960-09-27 | Xpreparation of hexahydrobenzoquinol- | ||
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US3053845A (en) * | 1962-09-11 | Benzofykedocolines | ||
| US3045021A (en) * | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
| GB999092A (en) * | 1959-11-24 | 1965-07-21 | Wellcome Found | Method for making benzo(a)-quinolizine derivatives |
| US3375254A (en) * | 1961-09-29 | 1968-03-26 | Burroughs Wellcome Co | Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines |
| US3105079A (en) * | 1961-12-29 | 1963-09-24 | Pfizer & Co C | 10-aminobenzopyridocolines |
| US3390152A (en) * | 1965-10-21 | 1968-06-25 | Abbott Lab | 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines |
| JPS4836303B1 (enExample) * | 1968-12-27 | 1973-11-02 | ||
| US3635986A (en) * | 1969-12-22 | 1972-01-18 | Miles Lab | 2-substituted amino-hexahydrobenzo(a)quinolizines |
| YU264675A (en) * | 1974-10-23 | 1982-05-31 | Chinoin Gyogyszer Es Vegyeszet | Process for obtaining benzo (a)-quinolizidine derivatives |
| GB1513824A (en) * | 1975-05-22 | 1978-06-14 | Wyeth John & Brother Ltd | 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative |
| US4133812A (en) * | 1975-11-21 | 1979-01-09 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Process for producing benzo (a) quinolizine derivatives |
| US4304913A (en) * | 1978-11-20 | 1981-12-08 | Miles Laboratories, Inc. | Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines |
| US4353656A (en) * | 1980-10-14 | 1982-10-12 | Xerox Corporation | Moving coil, multiple energy print hammer system including a closed loop servo |
| US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| AU591152B2 (en) * | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US6087376A (en) * | 1997-02-05 | 2000-07-11 | University Of Kentucky Research Foundation | Use of lobeline compounds in the treatment of central nervous system diseases and pathologies |
| FR2794742B1 (fr) * | 1999-06-11 | 2005-06-03 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
| US6632666B2 (en) * | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| PL1638529T3 (pl) * | 2003-06-16 | 2017-03-31 | Andrx Pharmaceuticals, Llc. | Kompozycja doustna o przedłużonym uwalnianiu |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) * | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| KR100682506B1 (ko) * | 2005-01-18 | 2007-02-15 | (주)젠크로스 | 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물 |
| GB0516168D0 (en) * | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| GB2463451A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
-
2005
- 2005-07-14 GB GBGB0514501.6A patent/GB0514501D0/en not_active Ceased
-
2006
- 2006-05-31 ME MEP-2008-916A patent/ME01629B/me unknown
- 2006-07-13 RS RSP-2008/0492A patent/RS50626B/sr unknown
- 2006-07-13 CA CA002615077A patent/CA2615077A1/en not_active Abandoned
- 2006-07-13 RU RU2008105590/15A patent/RU2409365C2/ru not_active IP Right Cessation
- 2006-07-13 PL PL06764942T patent/PL1885363T3/pl unknown
- 2006-07-13 AT AT06764942T patent/ATE409481T1/de active
- 2006-07-13 PT PT06764942T patent/PT1885363E/pt unknown
- 2006-07-13 HR HR20080677T patent/HRP20080677T3/xx unknown
- 2006-07-13 ES ES06764942T patent/ES2314931T3/es not_active Expired - Lifetime
- 2006-07-13 AT AT08017191T patent/ATE522215T1/de not_active IP Right Cessation
- 2006-07-13 DK DK06764942T patent/DK1885363T3/da active
- 2006-07-13 CN CNA2006800339758A patent/CN101282726A/zh active Pending
- 2006-07-13 AU AU2006268098A patent/AU2006268098B2/en not_active Ceased
- 2006-07-13 JP JP2008520952A patent/JP2009501202A/ja active Pending
- 2006-07-13 EP EP06764942A patent/EP1885363B1/en not_active Expired - Lifetime
- 2006-07-13 ZA ZA200800905A patent/ZA200800905B/xx unknown
- 2006-07-13 KR KR1020087003481A patent/KR20080030666A/ko not_active Withdrawn
- 2006-07-13 SI SI200630147T patent/SI1885363T1/sl unknown
- 2006-07-13 EP EP08017191A patent/EP2027861B1/en not_active Expired - Lifetime
- 2006-07-13 US US11/995,436 patent/US20080319000A1/en not_active Abandoned
- 2006-07-13 DE DE602006002982T patent/DE602006002982D1/de not_active Expired - Lifetime
- 2006-07-13 NZ NZ565522A patent/NZ565522A/en not_active IP Right Cessation
- 2006-07-13 WO PCT/GB2006/002593 patent/WO2007007105A1/en not_active Ceased
-
2008
- 2008-12-22 CY CY20081101475T patent/CY1108653T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006268098A1 (en) | 2007-01-18 |
| EP2027861B1 (en) | 2011-08-31 |
| NZ565522A (en) | 2010-04-30 |
| RU2008105590A (ru) | 2009-08-20 |
| JP2009501202A (ja) | 2009-01-15 |
| CY1108653T1 (el) | 2014-04-09 |
| ATE522215T1 (de) | 2011-09-15 |
| KR20080030666A (ko) | 2008-04-04 |
| DK1885363T3 (da) | 2008-12-08 |
| RS50626B (sr) | 2010-06-30 |
| HK1111085A1 (en) | 2008-08-01 |
| EP1885363B1 (en) | 2008-10-01 |
| EP2027861A1 (en) | 2009-02-25 |
| SI1885363T1 (sl) | 2009-02-28 |
| WO2007007105A1 (en) | 2007-01-18 |
| PL1885363T3 (pl) | 2009-05-29 |
| EP1885363A1 (en) | 2008-02-13 |
| CA2615077A1 (en) | 2007-01-18 |
| ME01629B (me) | 2010-06-30 |
| CN101282726A (zh) | 2008-10-08 |
| GB0514501D0 (en) | 2005-08-24 |
| ZA200800905B (en) | 2010-04-28 |
| PT1885363E (pt) | 2009-01-08 |
| RU2409365C2 (ru) | 2011-01-20 |
| ES2314931T3 (es) | 2009-03-16 |
| HRP20080677T3 (hr) | 2009-02-28 |
| DE602006002982D1 (de) | 2008-11-13 |
| US20080319000A1 (en) | 2008-12-25 |
| AU2006268098B2 (en) | 2011-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108653T1 (el) | Η εφευρεση αυτη σχετιζεται με τη χρηση διυδpotetpabenazinhς στην θεραπαυτικη αντιμετωπιση της νοσου huntington | |
| EA200970575A1 (ru) | Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения | |
| EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
| ZA200703110B (en) | Compounds, compositions and methods of inhibiting α-synuclein toxicity | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| ATE524479T1 (de) | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren | |
| CY1110901T1 (el) | Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος | |
| ATE534391T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen | |
| ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
| MY148985A (en) | 2-aminopyridine analogs as glucokinase activators | |
| JO2581B1 (en) | Substituted Arylsulfonamides | |
| DE602006019468D1 (de) | Diarylharnstoffe zur behandlung von pulmonaler hypertonie | |
| ATE494890T1 (de) | Alpha-aminoamid-derivate zur behandlung von suchtstörungen | |
| ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
| DE502006007982D1 (de) | Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
| DE502006008804D1 (de) | Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen | |
| WO2007058805A3 (en) | Compositions and methods for treating cns disorders | |
| ATE494008T1 (de) | Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen | |
| ATE495271T1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| BRPI0517972A (pt) | ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas | |
| DE602004013540D1 (de) | Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen | |
| ATE374202T1 (de) | Neue analoga von nitrobenzylthioinosin | |
| DE602005018179D1 (de) | Behandlung von krankheiten | |
| ATE478707T1 (de) | Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1885363 Country of ref document: EP |